EBIT: Income before interest and taxes.
Tango Therapeutics, Inc. (TNGX) had EBIT of $-59.78M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-55.34M |
|
-- |
|
-- |
|
$59.78M |
|
$-59.78M |
|
$4.45M |
|
$-55.34M |
|
$-55.34M |
|
$-55.34M |
|
$-55.34M |
|
$-55.34M |
|
$-55.34M |
|
|
EBIT |
$-59.78M |
$-60.30M |
|
149.88M |
|
149.88M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$1.03B |
|
$6.09M |
|
$42.21M |
|
$1.07B |
|
$20.30M |
|
-- |
|
$29.05M |
|
$49.35M |
|
$1.02B |
|
$1.02B |
|
$1.02B |
|
168.38M |
|
| Cash Flow Statement Financials | |
$-83.23M |
|
$-436.34M |
|
$752.41M |
|
$114.85M |
|
$347.70M |
|
$232.85M |
|
$27.69M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
50.82 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-83.20M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.40% |
|
-5.40% |
|
-5.15% |
|
-5.40% |
|
$6.08 |
|
$-0.56 |
|
$-0.56 |
|